Doug McMillon and Joaquin Duato are influential American business executives whose careers reflect two different approaches to serving consumers in a rapidly changing economy. McMillon led Walmart through
Doug McMillon and Joaquin Duato are influential American business executives whose careers reflect two different approaches to serving consumers in a rapidly changing economy. McMillon led Walmart through a period of significant retail transformation, while Duato has guided Johnson & Johnson through major changes in pharmaceuticals, medical technology, and corporate structure.
Their names are most meaningfully connected through the broader relationship between retail and healthcare. Walmart has long provided consumers with access to pharmacies, health-related products, and other services. Johnson & Johnson historically operated one of the world’s most recognizable consumer health businesses before separating it into an independent company called Kenvue in 2023.
These overlapping business interests offer an informative basis for comparing the two executives. However, they do not establish a direct personal relationship or a special partnership between McMillon and Duato.
Their leadership histories also require an important update. McMillon retired as Walmart’s president and CEO on January 31, 2026, with John Furner succeeding him on February 1. Duato remains Johnson & Johnson’s chairman and CEO as of October 2026.
Understanding their careers involves more than reviewing executive biographies. Their decisions illustrate how large corporations adapt to technological change, consumer expectations, healthcare innovation, and the challenges of maintaining profitable operations.
Doug McMillon is an American business executive best known for leading Walmart, one of the world’s largest retailers.
McMillon’s connection with Walmart began in 1984 when he joined the company as an hourly associate. His career subsequently developed through several areas of the business, including merchandising, international operations, and senior leadership.
Before becoming Walmart’s CEO, he held the position of president and CEO of Sam’s Club and later led Walmart International.
He became president and chief executive officer of Walmart Inc. in February 2014.
His appointment came during a period when traditional retailers faced intensifying competition from e-commerce companies and rapidly changing consumer shopping habits.
Over the following years, McMillon helped oversee Walmart’s expansion into online shopping, digital services, delivery infrastructure, and technology-enabled retail operations.
His leadership emphasized combining physical stores with digital platforms, an approach commonly described as omnichannel retailing.
Rather than treating stores and online shopping as entirely separate businesses, Walmart increasingly used its existing physical infrastructure to support digital orders, pickup services, and home delivery.
McMillon’s tenure involved several important priorities.
Walmart invested in its online operations while continuing to serve customers through its extensive store network. The company expanded services intended to make shopping more convenient across different channels.
It also introduced changes involving employee compensation, workplace benefits, technology, and operational processes.
McMillon’s strategy reflected a broader challenge in retail: consumers increasingly expected competitive prices, reliable product availability, convenient delivery, and digital shopping tools.
Meeting those expectations required investment in logistics, inventory systems, employee training, and customer-facing technology.
Walmart also participated in sectors extending beyond conventional grocery and general merchandise retail, including pharmacy services, optical care, and selected healthcare initiatives.
Those activities help explain why McMillon’s career is relevant to discussions about the American healthcare marketplace.
On November 14, 2025, Walmart announced that John Furner would succeed McMillon as president and CEO.
The leadership transition took effect on February 1, 2026.
McMillon retired from the chief executive position on January 31 after approximately 12 years leading Walmart.
The announcement also outlined transitional board arrangements intended to support the change in leadership.
Consequently, describing McMillon as Walmart’s current CEO would be inaccurate.
His significance today rests largely on the strategic decisions and organizational changes associated with his tenure.
Joaquin Duato is a business executive who serves as chairman and chief executive officer of Johnson & Johnson.
Duato became Johnson & Johnson’s CEO on January 3, 2022, succeeding Alex Gorsky.
In January 2023, he assumed the additional role of chairman of the company’s board of directors.
His professional history with Johnson & Johnson extends across decades and includes leadership responsibilities in different geographic markets and business functions.
Before becoming CEO, Duato held senior positions involving pharmaceutical operations and the company’s broader executive leadership.
His experience within the organization gave him exposure to healthcare businesses operating under different regulatory systems, competitive conditions, and scientific priorities.
Unlike McMillon, whose career developed primarily in retail, Duato’s professional background centers on healthcare products, medical innovation, and the commercial development of therapies and technologies.
Duato assumed the CEO role during an important period of corporate transformation.
Johnson & Johnson had already announced plans to separate its consumer health business from its pharmaceutical and medical technology operations.
The separation was completed in 2023, creating an independent publicly traded consumer health company called Kenvue.
Under Duato’s leadership, Johnson & Johnson increasingly concentrated on two primary areas: Innovative Medicine and MedTech.
Innovative Medicine includes prescription therapies and research programs focused on treating diseases.
MedTech encompasses medical devices, surgical technologies, and other healthcare equipment used by medical professionals.
The company’s strategic priorities include oncology, immunology, neuroscience, cardiovascular medicine, surgery, and vision.
These areas differ considerably from ordinary consumer retail products because their development, manufacturing, distribution, and use involve specialized scientific and regulatory requirements.
As of October 2026, Duato continues to serve as chairman and CEO of Johnson & Johnson.
The company’s third-quarter 2026 results, announced on October 13, reported approximately $25.4 billion in quarterly sales.
The results highlighted growth in Innovative Medicine alongside challenges in certain medical technology businesses.
The company’s continuing focus on healthcare innovation distinguishes Duato’s leadership from the consumer retail strategy associated with McMillon.
The clearest connection between Doug McMillon and Joaquin Duato is the intersection of retail and healthcare, particularly the historic presence of Johnson & Johnson consumer health brands in mass-market retail channels.
Walmart sells health-related products and operates pharmacy services. Johnson & Johnson historically developed and marketed consumer products that became familiar to shoppers throughout the United States.
Products such as Tylenol, Band-Aid adhesive bandages, and Johnson’s baby care products illustrate the kind of consumer health merchandise sold through major retail channels.
However, these brands no longer belong to Johnson & Johnson.
They became part of Kenvue, which completed its separation from Johnson & Johnson in August 2023.
This distinction is essential when discussing the relationship between the two companies.
A retailer’s sale of products from a manufacturer’s portfolio also does not establish a direct partnership between the companies’ CEOs.
Large businesses operate through procurement teams, distribution agreements, suppliers, wholesalers, and commercial departments. Senior executives may oversee those systems without personally negotiating individual product relationships.
No reliable public documentation identified for this article establishes that McMillon and Duato formed a joint venture, announced a personal business partnership, or collaborated on a specific healthcare initiative.
Their connection is therefore best understood through overlapping industries and corporate strategy rather than a confirmed direct relationship.
The relationship between retail and healthcare has developed over decades.
Many consumers purchase basic health-related products at the same stores where they buy groceries, clothing, and household necessities.
Large retail chains provide access to products such as first-aid supplies, personal care items, and nonprescription medicines.
Healthcare manufacturers, meanwhile, depend on distribution networks that allow their products to reach customers.
Walmart and the former consumer health division of Johnson & Johnson historically operated on different sides of this commercial system.
Walmart offered retail access to customers. Johnson & Johnson supplied recognized consumer healthcare brands through established distribution channels.
The existence of these complementary business activities helps explain their relevance to one another.
However, retail distribution differs from healthcare delivery.
Selling a nonprescription product does not make a retailer equivalent to a pharmaceutical manufacturer, medical device developer, or hospital.
Each business operates under different economic conditions and regulatory responsibilities.
Under McMillon’s leadership, Walmart continued developing services connected to health and wellness.
Its pharmacy operations provided access to prescription medications, immunizations, and other pharmacy-related services.
The company also maintained optical services through Walmart Vision Centers.
These activities supported Walmart’s broader retail model by placing certain healthcare services alongside everyday consumer shopping.
For some communities, retail pharmacies can provide a convenient location for accessing routine medications and eligible preventive services.
However, pharmacy services are not substitutes for every form of medical care.
Complex medical conditions, emergency treatment, and specialized procedures require appropriate healthcare professionals and facilities.
Walmart’s approach reflected an effort to combine convenience, physical accessibility, and retail infrastructure while operating within the requirements of healthcare services.
Before the Kenvue separation, Johnson & Johnson owned consumer brands familiar to generations of American shoppers.
Its portfolio included products associated with pain relief, first aid, skin care, oral care, and baby care.
This consumer health business connected Johnson & Johnson to the retail environment in which Walmart operated.
A widely recognized product could benefit from distribution through mass retailers, drugstores, and other channels.
Retailers, in turn, could offer established brands that shoppers already recognized.
But the business relationship was not the same as a merger or a joint executive venture.
Manufacturers and retailers typically maintain separate organizations, financial interests, and strategic priorities even when their products reach the same customers.
That distinction became especially important after Johnson & Johnson separated its consumer health business.
One of the most consequential developments during Duato’s leadership was the separation of Johnson & Johnson’s consumer health operations.
Johnson & Johnson announced its intention to pursue the separation in November 2021, before Duato became CEO.
He subsequently oversaw important stages of the process.
The new company, Kenvue, completed its initial public offering in May 2023 and became fully independent in August 2023.
The transaction allowed Johnson & Johnson to concentrate on pharmaceuticals and medical technology while creating a separate business focused on consumer health products.
Consumer products and advanced medical technologies have different business characteristics.
A consumer skincare brand may compete through product positioning, advertising, pricing, customer loyalty, and retail shelf availability.
A prescription medicine requires scientific research, clinical evaluation, regulatory authorization, specialized manufacturing, and appropriate prescribing practices.
Medical devices also involve technical development, quality systems, regulatory oversight, and relationships with healthcare providers.
Separating these activities gave each company a more distinct strategic focus.
For Johnson & Johnson, the transaction increased its emphasis on innovative medicines and medical technologies.
For Kenvue, independence created a corporate structure centered on consumer health brands and their distribution through retail markets.
Walmart’s consumer health assortment includes familiar product categories historically associated with Johnson & Johnson.
However, the ownership of many well-known brands changed following the Kenvue separation.
Tylenol, Neutrogena, Listerine, Band-Aid, and Johnson’s baby care products became part of Kenvue rather than remaining within Johnson & Johnson’s current operating portfolio.
This is important for readers researching Doug McMillon and Joaquin Duato because older descriptions of Johnson & Johnson’s consumer business may no longer reflect the company’s present structure.
An additional development emerged in November 2025, when Kimberly-Clark announced an agreement to acquire Kenvue.
By October 2026, the proposed transaction had received conditional European Union approval, although regulatory approval should not be confused with the completion of an acquisition.
The evolving ownership of consumer health brands further illustrates why current company information matters.
Walmart’s attempt to expand more directly into healthcare delivery provides another useful comparison between the business strategies associated with McMillon and Duato.
In 2019, Walmart launched Walmart Health centers.
These locations were designed to provide selected healthcare services in a retail-associated setting.
The initiative represented an attempt to address consumer demand for accessible healthcare while building on Walmart’s established physical presence.
However, the initiative faced substantial economic challenges.
On April 30, 2024, Walmart announced that it would close all 51 Walmart Health centers across five states and discontinue Walmart Health Virtual Care.
The company attributed the decision to an unsustainable business model, citing reimbursement challenges and increasing operating costs.
The announcement illustrated an important distinction between operating a large retailer and delivering clinical healthcare services.
Healthcare facilities must address professional staffing, insurance reimbursement, regulatory requirements, patient scheduling, and continuity of care.
These responsibilities can create cost structures that differ substantially from those of ordinary retail stores.
Even a company with Walmart’s scale may find that operating specific clinical services does not produce an economically sustainable model.
The closure did not mean Walmart was abandoning every health-related business.
Its pharmacies, vision centers, and other health and wellness activities remained separate from the discontinued clinic initiative.
The contrast is significant.
Walmart experimented with providing selected clinical services directly to consumers but eventually discontinued that clinic model.
Johnson & Johnson, under Duato, continued concentrating on developing medicines and medical technologies.
The two companies therefore approached healthcare from different positions in the industry.
Walmart’s strengths included retail distribution, customer access, logistics, and physical store infrastructure.
Johnson & Johnson’s strengths centered on scientific research, regulated healthcare products, and medical technology development.
Neither business model can be evaluated solely by comparing revenue or company size.
Their operating risks, customer relationships, investment requirements, and regulatory obligations are fundamentally different.
| Area | Doug McMillon | Joaquin Duato |
|---|---|---|
| Best-known company | Walmart | Johnson & Johnson |
| Executive role | Former president and CEO | Chairman and CEO |
| CEO tenure | February 2014–January 2026 | January 2022–present |
| Primary industry | Retail and e-commerce | Pharmaceuticals and medical technology |
| Career development | Progressed through Walmart’s retail operations | Progressed through Johnson & Johnson’s healthcare businesses |
| Major strategic focus | Omnichannel retail and digital transformation | Innovative Medicine and MedTech |
| Healthcare connection | Pharmacies, optical services, and former Walmart Health initiative | Medicines, medical devices, and former consumer health operations |
| Major corporate development | Walmart’s digital transformation | Kenvue separation |
| Direct business partnership between the executives | Not publicly established | Not publicly established |
The comparison highlights how both executives managed change within established companies while responding to very different competitive environments.
One of McMillon’s central challenges was maintaining Walmart’s relevance as consumers increasingly embraced online shopping.
The company’s physical stores remained valuable, but customers expected greater convenience and flexibility.
Walmart responded by integrating digital ordering, fulfillment operations, and delivery services with its traditional retail business.
This transformation required investment in technology, data, logistics, and employees.
The objective was not simply to copy online-only competitors.
Walmart increasingly used its store network as an advantage in serving customers through multiple shopping channels.
McMillon’s tenure became closely associated with this effort to transform a conventional retailer into a more technologically integrated company.
Duato’s leadership has involved different priorities.
Johnson & Johnson invests in developing medicines and technologies intended to address medical needs.
Innovation in healthcare can involve lengthy development timelines, substantial research spending, clinical trials, regulatory review, and commercial uncertainty.
The company must evaluate scientific opportunities alongside manufacturing capability, market access, and patient outcomes.
Duato’s strategic direction has emphasized selected areas of healthcare where Johnson & Johnson believes it possesses capabilities to develop differentiated products.
The Kenvue separation supported that focus by removing the consumer health business from the company’s principal operating structure.
Both executives have emphasized technology, but its application differs between their industries.
For Walmart, digital technology can improve inventory management, online shopping, fulfillment, employee productivity, and customer experiences.
For Johnson & Johnson, technology can support scientific research, pharmaceutical development, medical procedures, and healthcare innovation.
Artificial intelligence is increasingly relevant to both fields.
In retail, AI may help businesses analyze demand, improve supply chains, or support customers.
In healthcare, AI may assist research, data analysis, and certain medical technology applications, subject to appropriate validation and oversight.
The presence of AI in both industries does not establish that McMillon and Duato collaborated on a shared technology project.
It instead demonstrates how a major technological development can influence businesses with very different purposes.
Established corporations face a difficult balancing act.
They must preserve the strengths that made them successful while responding to new technology, changing markets, and evolving customer expectations.
Walmart and Johnson & Johnson illustrate different versions of this challenge.
Walmart needed to adapt a large physical retail network to a more digital consumer economy.
Johnson & Johnson needed to focus its portfolio while maintaining investment in scientific innovation.
Both companies made significant strategic decisions that affected their organizational structures.
However, transformation does not guarantee that every initiative will succeed.
Walmart’s closure of its health centers illustrates the challenges of expanding into a business with unfamiliar economics.
Johnson & Johnson’s separation of Kenvue illustrates a different response: changing corporate structure to concentrate resources on selected operations.
These outcomes demonstrate why large organizations must continually evaluate which activities support their long-term strategies.
Business growth does not always require expanding into additional industries.
Sometimes companies become more focused by reducing the number of activities they operate.
Walmart’s healthcare-center closures and Johnson & Johnson’s consumer health separation are examples of different forms of strategic adjustment.
The circumstances were not identical.
Walmart discontinued a service model it determined was financially unsustainable.
Johnson & Johnson separated an established consumer products business into an independent company as part of a broader portfolio strategy.
Both developments involved reconsidering how corporate resources could be deployed.
For readers interested in business leadership, this distinction is more useful than treating every expansion or divestiture as an automatic success or failure.
| Year | Important development |
|---|---|
| 1984 | Doug McMillon begins his Walmart career. |
| 2014 | McMillon becomes Walmart’s president and CEO. |
| 2019 | Walmart launches Walmart Health centers. |
| November 2021 | Johnson & Johnson announces plans to separate its consumer health business. |
| January 2022 | Joaquin Duato becomes Johnson & Johnson’s CEO. |
| January 2023 | Duato becomes chairman of Johnson & Johnson. |
| August 2023 | Kenvue completes its separation from Johnson & Johnson. |
| April 2024 | Walmart announces the closure of Walmart Health centers and virtual care operations. |
| November 2025 | Walmart announces McMillon’s retirement and John Furner’s appointment. |
| January 2026 | McMillon retires as Walmart CEO. |
| February 2026 | John Furner assumes Walmart’s CEO position. |
| October 2026 | Duato continues leading Johnson & Johnson, which reports third-quarter sales of approximately $25.4 billion. |
This chronology establishes their career milestones without implying that decisions at one company were coordinated with the other.
No reliable public documentation identified during research establishes a personal friendship, family relationship, or direct private business partnership between Doug McMillon and Joaquin Duato.
That does not prove they have never met, attended the same event, or communicated professionally.
Executives leading major American corporations may participate in business conferences, industry organizations, and discussions about economic issues.
However, shared prominence in the corporate world is not sufficient evidence of a personal relationship.
The strongest supported connection between McMillon and Duato remains their leadership of companies with historically overlapping interests in consumer healthcare.
The careers of these executives provide several lessons relevant to business management.
First, experience within an organization can support leadership development.
McMillon progressed from an hourly retail position to the highest executive office at Walmart. Duato advanced through a long career at Johnson & Johnson before becoming CEO.
Second, large corporations must adapt to changing market conditions.
Walmart expanded its digital capabilities as consumer behavior changed. Johnson & Johnson reorganized its business around medicines and medical technologies.
Third, business decisions require a clear understanding of operating economics.
Walmart’s experience with healthcare centers demonstrates that an established company can encounter difficulties when entering a service sector with different financial requirements.
Finally, organizational focus matters.
Johnson & Johnson’s separation of Kenvue illustrates how a corporation may choose to concentrate on specific industries rather than continuing to operate businesses across a broader portfolio.
These examples offer useful insights without suggesting that either executive followed a universally applicable formula for success.
No direct business partnership between the two executives has been established by reliable public documentation reviewed for this article. Their connection is primarily through overlapping retail and healthcare industries.
There is no verified record establishing that McMillon worked for Johnson & Johnson. His professional career is principally associated with Walmart and its related businesses.
No. McMillon retired as Walmart’s president and CEO on January 31, 2026. John Furner succeeded him on February 1, 2026.
Yes. As of October 17, 2026, Duato serves as chairman and CEO of Johnson & Johnson.
No. Those brands became part of Kenvue following its separation from Johnson & Johnson in 2023.
No. Walmart and Johnson & Johnson remain separate corporations. Their historic participation in the consumer health marketplace does not constitute a merger.
McMillon’s leadership focused primarily on retail operations, digital commerce, and customer access. Duato’s leadership centers on pharmaceutical research, healthcare technology, and medical innovation.
The relationship between Doug McMillon and Joaquin Duato is best understood through their leadership of two major American corporations operating in different but historically overlapping markets.
McMillon helped transform Walmart into a more digitally integrated retailer while overseeing business activities that included pharmacy services and selected healthcare initiatives. Duato has led Johnson & Johnson through a period of corporate restructuring and greater concentration on innovative medicines and medical technology.
The separation of Johnson & Johnson’s consumer health business into Kenvue changed the corporate ownership behind many familiar products historically distributed through major retailers.
Although no direct personal or business partnership between McMillon and Duato has been established, their careers provide a useful comparison of corporate strategy, organizational change, and the evolving relationship between retail and healthcare.
Their experiences also demonstrate that successful business leadership involves more than expansion. It requires deciding where a company can create lasting value, adapting to changing conditions, and reconsidering strategies when circumstances demand a different approach.
ALSO READ: Miguel Patricio and Albert Bourla: Careers, Leadership, and Achievements
